Literature DB >> 20603408

21 years of biologically effective dose.

J F Fowler1.   

Abstract

In 1989 the British Journal of Radiology published a review proposing the term biologically effective dose (BED), based on linear quadratic cell survival in radiobiology. It aimed to indicate quantitatively the biological effect of any radiotherapy treatment, taking account of changes in dose-per-fraction or dose rate, total dose and (the new factor) overall time. How has it done so far? Acceptable clinical results have been generally reported using BED, and it is in increasing use, although sometimes mistaken for "biologically equivalent dose", from which it differs by large factors, as explained here. The continuously bending nature of the linear quadratic curve has been questioned but BED has worked well for comparing treatments in many modalities, including some with large fractions. Two important improvements occurred in the BED formula. First, in 1999, high linear energy transfer (LET) radiation was included; second, in 2003, when time parameters for acute mucosal tolerance were proposed, optimum overall times could then be "triangulated" to optimise tumour BED and cell kill. This occurs only when both early and late BEDs meet their full constraints simultaneously. New methods of dose delivery (intensity modulated radiation therapy, stereotactic body radiation therapy, protons, tomotherapy, rapid arc and cyberknife) use a few large fractions and obviously oppose well-known fractionation schedules. Careful biological modelling is required to balance the differing trends of fraction size and local dose gradient, as explained in the discussion "How Fractionation Really Works". BED is now used for dose escalation studies, radiochemotherapy, brachytherapy, high-LET particle beams, radionuclide-targeted therapy, and for quantifying any treatments using ionising radiation.

Entities:  

Mesh:

Year:  2010        PMID: 20603408      PMCID: PMC3473681          DOI: 10.1259/bjr/31372149

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  79 in total

1.  Time factors in larynx tumor radiotherapy: lag times and intertumor heterogeneity in clinical datasets from four centers.

Authors:  S A Roberts; J H Hendry
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-12-01       Impact factor: 7.038

2.  Stereotactic body radiation therapy for inoperable early stage lung cancer.

Authors:  Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy
Journal:  JAMA       Date:  2010-03-17       Impact factor: 56.272

3.  Accelerated hyperfractionated irradiation for advanced head and neck cancer: effect of shortening the median treatment duration by 13 days.

Authors:  F Leborgne; J H Leborgne; J Fowler; E Zubizarreta; J Mezzera
Journal:  Head Neck       Date:  2001-08       Impact factor: 3.147

4.  The radiobiology of conventional radiotherapy and its application to radionuclide therapy.

Authors:  Roger Dale; Alejandro Carabe-Fernandez
Journal:  Cancer Biother Radiopharm       Date:  2005-02       Impact factor: 3.099

5.  Radiobiological modelling of the therapeutic ratio for the addition of synchronous chemotherapy to radiotherapy in locally advanced squamous cell carcinoma of the head and neck.

Authors:  A Hartley; P Sanghera; J Glaholm; H Mehanna; C McConkey; J Fowler
Journal:  Clin Oncol (R Coll Radiol)       Date:  2009-10-31       Impact factor: 4.126

6.  The potential for mathematical modelling in the assessment of the radiation dose equivalent of cytotoxic chemotherapy given concomitantly with radiotherapy.

Authors:  B Jones; R G Dale
Journal:  Br J Radiol       Date:  2005-10       Impact factor: 3.039

7.  Medium-dose-rate brachytherapy of cancer of the cervix: preliminary results of a prospectively designed schedule based on the linear-quadratic model.

Authors:  F Leborgne; J F Fowler; J H Leborgne; E Zubizarreta; R Curochquin
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-03-15       Impact factor: 7.038

8.  Radiation-induced changes in cellularity and proliferation in human oral mucosa.

Authors:  Wolfgang Dörr; Christopher S Hamilton; Teresa Boyd; Barry Reed; James W Denham
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-03-15       Impact factor: 7.038

9.  Optimum overall times II: Extended modelling for head and neck radiotherapy.

Authors:  J F Fowler
Journal:  Clin Oncol (R Coll Radiol)       Date:  2007-12-26       Impact factor: 4.126

10.  How worthwhile are short schedules in radiotherapy? A series of exploratory calculations.

Authors:  J F Fowler
Journal:  Radiother Oncol       Date:  1990-06       Impact factor: 6.280

View more
  156 in total

1.  The BJR and progress in radiobiological modelling.

Authors:  R G Dale
Journal:  Br J Radiol       Date:  2010-07       Impact factor: 3.039

2.  Stochastic process pharmacodynamics: dose timing in neonatal gentamicin therapy as an example.

Authors:  Tomas Radivoyevitch; Nopphon Siranart; Lynn Hlatky; Rainer Sachs
Journal:  AAPS J       Date:  2015-02-07       Impact factor: 4.009

3.  Optimal solution for a cancer radiotherapy problem.

Authors:  A Bertuzzi; C Bruni; F Papa; C Sinisgalli
Journal:  J Math Biol       Date:  2013-01       Impact factor: 2.259

4.  Intensity-modulated and hypofractionated simultaneous integrated boost adjuvant breast radiation employing statics ports of tomotherapy (TomoDirect): a prospective phase II trial.

Authors:  Pierfrancesco Franco; Michele Zeverino; Fernanda Migliaccio; Domenico Cante; Piera Sciacero; Valeria Casanova Borca; Paolo Torielli; Cecilia Arrichiello; Giuseppe Girelli; Maria Rosa La Porta; Santi Tofani; Gianmauro Numico; Umberto Ricardi
Journal:  J Cancer Res Clin Oncol       Date:  2013-11-30       Impact factor: 4.553

Review 5.  Radiobiological considerations in combining doses from external beam radiotherapy and brachytherapy for cervical cancer.

Authors:  Ana M Tornero-López; Damián Guirado
Journal:  Rep Pract Oncol Radiother       Date:  2018-07-02

6.  Outcomes of stereotactic radiosurgery and hypofractionated stereotactic radiotherapy for refractory Cushing's disease.

Authors:  Alexander D Sherry; Mohamed H Khattab; Mark C Xu; Patrick Kelly; Joshua L Anderson; Guozhen Luo; Andrea L Utz; Lola B Chambless; Anthony J Cmelak; Albert Attia
Journal:  Pituitary       Date:  2019-12       Impact factor: 4.107

7.  Repopulation of interacting tumor cells during fractionated radiotherapy: stochastic modeling of the tumor control probability.

Authors:  Hatim Fakir; Lynn Hlatky; Huamin Li; Rainer Sachs
Journal:  Med Phys       Date:  2013-12       Impact factor: 4.071

8.  Setup margins and geometric uncertainties in intensity-modulated radiation therapy in treating pituitary adenomas: the experience of Lyon Sud Hospital.

Authors:  B De Bari; I Shakir Shakir; T Chekrine; L Lestrade; V Favrel
Journal:  Radiol Med       Date:  2012-10-22       Impact factor: 3.469

9.  An Institutional Audit of Maximum Heart Dose in Patients Treated With Palliative Radiotherapy for Non-small Cell Lung Cancer.

Authors:  Carsten Nieder; Kristian S Imingen
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

Review 10.  Combining brachytherapy and immunotherapy to achieve in situ tumor vaccination: A review of cooperative mechanisms and clinical opportunities.

Authors:  Ravi B Patel; Claire C Baniel; Raghava N Sriramaneni; Kristin Bradley; Stephanie Markovina; Zachary S Morris
Journal:  Brachytherapy       Date:  2018-08-02       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.